Interestingly, lean NAFLD patients have significantly higher FXR activity and a distinct microbiota profile, but their favorable metabolic profile not help resist hepatic lipid accumulation [203]. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.